Across TCGA pan-cancer cohorts, LINC01811 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated LINC01811 data layer.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher LINC01811 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01811 expression acts as an unfavorable survival marker, although some lineages such as STAD and COAD show a favorable association.
ESCA, STAD, and COAD are the cancer types where LINC01811 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.